AN2 Therapeutics Insider Day Lucy Files Form 4
| Field | Detail |
|---|---|
| Company | Day Lucy |
| Form Type | 4 |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $3.91 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-filing, ownership-change, form-4
TL;DR
**Day Lucy, an AN2 Therapeutics insider, filed a Form 4, but the filing lacks transaction details.**
AI Summary
This Form 4 filing, dated March 23, 2026, reports a change in beneficial ownership for Day Lucy, an insider at AN2 Therapeutics, Inc. (CIK: 0001880438). While the filing details the reporting person and the issuer, it does not specify the nature or amount of the transaction (e.g., a buy or sell). This matters to investors because insider transactions can signal management's confidence (or lack thereof) in the company's future, but without transaction details, its specific impact is unclear.
Why It Matters
Insider filings like this can indicate management's view of the company's prospects, but without transaction specifics, its immediate impact on stock valuation is limited.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not disclose any specific transaction that would inherently increase or decrease risk.
Analyst Insight
Investors should monitor subsequent filings or news from AN2 Therapeutics for details on Day Lucy's transaction to understand its potential implications, as this filing alone provides insufficient information for action.
Key Players & Entities
- Day Lucy (person) — Reporting Person
- AN2 Therapeutics, Inc. (company) — Issuer
- 0001914510 (person) — CIK for Day Lucy
- 0001880438 (company) — CIK for AN2 Therapeutics, Inc.
FAQ
What is the purpose of this Form 4 filing?
This Form 4 filing, dated March 23, 2026, is a 'Statement of changes in beneficial ownership of securities' for Day Lucy, an insider of AN2 Therapeutics, Inc., as required by the SEC. It indicates that there was a change in their beneficial ownership, but the specific details of the transaction (e.g., shares bought or sold, price) are not provided in the summary information.
Who is the issuer mentioned in this filing?
The issuer mentioned in this filing is AN2 Therapeutics, Inc., with CIK 0001880438. Their business address is 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025.
Filing Stats: 893 words · 4 min read · ~3 pages · Grade level 7.5 · Accepted 2026-03-23 19:16:42
Key Financial Figures
- $3.91 — 1. The exercise price of the option is $3.91 per share, representing the closing pri
Filing Documents
- ownership.html (4)
- ownership.xml (4) — 15KB
- 0001193125-26-120236.txt ( ) — 16KB
From the Filing
SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Day Lucy (Last) (First) (Middle) C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100 (Street) MENLO PARK CALIFORNIA 94025 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol AN2 Therapeutics, Inc. [ ANTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 73,665 (2) 04/29/2031 Common Stock 73,665 (3) 73,665 D Stock Option (right to buy) $ 6.596 03/19/2026 D 73,665 (2) 04/29/2031 Common Stock 73,665 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 66,000 (4) 05/11/2032 Common Stock 66,000 (3) 66,000 D Stock Option (right to buy) $ 17.28 03/19/2026 D 66,000 (4) 05/11/2032 Common Stock 66,000 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 82,300 (5) 02/14/2033 Common Stock 82,300 (3) 82,300 D Stock Option (right to buy) $ 14.29 03/19/2026 D 82,300 (5) 02/14/2033 Common Stock 82,300 (3) 0 D Explanation of Responses: 1. The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. 2. The option is fully vested. 3. On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. 4. The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. 5. The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Lucy Day 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of secur